MUO on MSN

The Windows Registry sounds scary until you see what it can actually do

The scariest part of Windows might just be its most useful tool.

CT Senate passes consumer data protection legislation

SB 4, wide-ranging legislation that establishes restrictions on how data brokers can use consumer information, passed the ...

First Nations file new claims against B.C. government, cite court ruling making UNDRIP enforceable in law

Attorney general's office won't release Premier David Eby's list of more than 20 amended claims against the province ...
PharmiWeb

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...

The scientist, the survivor and the medical mystery thought unsolvable

In a bar, a poet meets the man behind the drug that saved his life — discovering how science, faith and chance created a ...
CSO Online

Top techniques attackers use to infiltrate your systems today

Popular tool abuse, ClickFix, and identity-based attacks are among the most prevalent techniques bad actors are deploying ...
The Manila Times

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...